EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Circulating tumor DNA ( ctDNA ) trajectories predict survival in trifluridine/tipiracil‐treated metastatic colorectal cancer patients

Matthias Unseld, Stefan Kühberger iD, Ricarda Graf, Christine Beichler, Markus Braun, Nadia Dandachi iD, Ellen Heitzer iD, Gerald W Prager iD

Molecular Oncology · 2025-07 · 19 (7) · 2120-2132

DOI: 10.1002/1878-0261.13755 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Molecular Oncology, online erschienen am 22.01.2025. Verfasst von Matthias Unseld und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Palliative Care, Department of Medicine I, Medical University of Vienna, Austria. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Circulating Tumor DNA, Colorectal Neoplasms, Pyrrolidines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Federal Ministry for Digital and Economic Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Late‐line treatment in metastatic colorectal cancer (mCRC) can improve prognosis. However, not every patient has a benefit and may experience severe side effects. Thus, predictive/prognostic biomarkers are urgently needed. We investigated the prognostic role of circulating tumor DNA (ctDNA) in mCRC patients before and during treatment with trifluridine/tipiracil (FTD/TPI). This noninterventional translational biomarker phase II study enrolled 30 mCRC patients (60% male, 40% female). Using a 77‐gene panel, ctDNA was detectable in 90% of patients. Tumor levels were assessed based on aneuploidy (ichorCNA) as well as the highest variant allele frequency, and correlated with overall survival (OS). Uni‐ and multivariate survival analyses were performed with clinical variables. Longitudinal changes in tumor levels over time were analyzed with linear mixed and joint models. The median OS was 8.1 months, with a recorded disease control rate of 30%. High ctDNA levels (≥ 5%) were associated with inferior survival after undergoing FTD/TPI therapy. Elevated tumor level trajectories over time were associated with higher risks of death. Therefore, ctDNA can help identify patients who are unlikely to benefit significantly from this treatment in late‐stage disease, thus preventing unnecessary treatments and their associated side effects, ultimately enhancing quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCirculating Tumor DNAColorectal NeoplasmsPyrrolidinesTrifluridineAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedBiomarkers, TumorDrug CombinationsPrognosisThymine

Stichwörter der Autor:innen

circulating tumor DNAjoint modelmetastatic colorectal cancermixed modelmolecular profilingtrifluridine/tipiracil

Substanzen

Biomarkers, TumorCirculating Tumor DNADrug CombinationsPyrrolidinesThymineTrifluridinetrifluridine tipiracil drug combination

Autor:innen und Institutionen

  • Division of Palliative Care, Department of Medicine I, Medical University of Vienna, Austria.
  • Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Austria.
  • Christian Doppler Laboratory for Liquid Biopsies for Early Detection of Cancer, Medical University of Graz, Austria.
  • Division of Oncology, Department of Internal Medicine, Medical University of Graz, Austria.
  • Research Unit for Epigenetic and Genetic Cancer Biomarkers, Medical University of Graz, Austria.
  • Division of Oncology, Department of Medicine I, Medical University of Vienna, Austria.

ORCID-Profile: Stefan Kühberger, Nadia Dandachi, Ellen Heitzer, Gerald W Prager

Förderung

  • Austrian Federal Ministry for Digital and Economic Affairs

Zitieren

APA

Unseld, M., Kühberger, S., Graf, R., Beichler, C., Braun, M., Dandachi, N., Heitzer, E., & Prager, G. W. (2025). Circulating tumor DNA ( ctDNA ) trajectories predict survival in trifluridine/tipiracil‐treated metastatic colorectal cancer patients. Molecular Oncology, 19(7), 2120-2132. https://doi.org/10.1002/1878-0261.13755

Vancouver

Unseld M, Kühberger S, Graf R, Beichler C, Braun M, Dandachi N, et al. Circulating tumor DNA ( ctDNA ) trajectories predict survival in trifluridine/tipiracil‐treated metastatic colorectal cancer patients. Molecular Oncology. 2025;19(7):2120-2132. doi:10.1002/1878-0261.13755

BibTeX
@article{Unseld2025,
  author = {Unseld, Matthias and Kühberger, Stefan and Graf, Ricarda and Beichler, Christine and Braun, Markus and Dandachi, Nadia and Heitzer, Ellen and Prager, Gerald W},
  title = {Circulating tumor DNA ( ctDNA ) trajectories predict survival in trifluridine/tipiracil‐treated metastatic colorectal cancer patients},
  journal = {Molecular Oncology},
  year = {2025},
  volume = {19},
  number = {7},
  pages = {2120--2132},
  doi = {10.1002/1878-0261.13755}
}
Kostenlos starten →